
Home / Clinics Supported / Sexual Wellness / Women's Sexual Health
Women in this category have usually been dismissed at least once before they walk through your door. The clinic that takes the conversation seriously doesn't just win the visit, it wins the next decade of that patient's care.
Book a Strategy CallNo medical background is required to own the business. An independent, state-licensed Medical Director directs all clinical care.
In a survey of 32,000 U.S. women, 43 percent reported a sexual problem and 12 percent said it caused them distress (Obstetrics & Gynecology, 2008).
The overlap with menopause care is large, and U.S. searches for “menopause treatment” run 1,000 to 10,000 a month (Google Keyword Planner). Few clinics are built for this half of the market, and that is the opportunity.
Our program to start a health and wellness clinic takes you from market review to opening day, with no franchise fees or royalties.
The women's category is not underserved because the demand is not there. It is underserved because many operators default to the men's model and never look at the other half of the market.
Google Keyword Planner, U.S., Sep 2025 to Aug 2026, in the ranges Google reports. “Women's sexual health” returns no figure. Local demand varies by market.
How clinics in this category are commonly structured: a business model, not clinical outcomes, which are for your Medical Director and the evidence to determine.
The anchor service line for many clinics here, with telehealth follow-up where state rules allow. Menopause care overlaps heavily with sexual health.
Platelet-rich plasma drawn and returned to the same patient in one visit, offered under generic procedure names.
Comprehensive lab work and structured intake. Where patients have often been dismissed elsewhere, a thorough workup is the trust-builder.
Widely marketed here and the biggest compliance exposure in the category. Read the regulatory section below before building any service line on these.
Pelvic floor physical therapy and specialist referrals, usually as partnerships rather than in-house.
Often positioned inside a broader women's health practice with biomarker panels, nutrition, and IV therapy.
On July 30, 2018, the FDA issued a safety communication on energy-based devices marketed for vaginal cosmetic procedures. Its position was direct: the agency has not cleared or approved any energy-based device for these procedures, or for symptoms related to menopause, urinary incontinence, or sexual function, and the safety and effectiveness of such use has not been established.
The FDA also sent letters to seven device manufacturers over how these products were marketed.
A device rep can show you a 510(k) clearance that is entirely real, for a general gynecological indication that has nothing to do with what the marketing implies. The clinic making the claim carries the exposure, not the manufacturer who supplied the brochure.
Nobody selling you a women's health clinic build is going to open with this. We do, because the operators who get this wrong find out from a regulator instead of from a consultant.
Not the brochure or the rep's summary: the actual clearance and the exact indication it covers. ACG helps you read what it does and does not authorize.
The FDA noted the term is not clearly defined, and it sits at the center of the enforcement history. ACG builds language that describes what you offer without it.
Once it is on your site, it is your claim to defend. ACG's marketing audit checks every service description against what your products are authorized for.
Hormone care, diagnostics, and autologous procedures sit in a very different posture than energy-based devices used off-label. Sequence the build accordingly.
Structured intake, genuine informed consent and clean records protect the practice if a claim is ever questioned. A licensed physician approves protocols, devices and consent before the first patient.
Insurance coverage here is inconsistent, so patients pay at the point of service. A woman who has been brushed off by two or three providers and then finds a practice that listens comes back for hormone care, menopause management and longevity services, and she tells other women. ACG plans each step with you, from market analysis to opening day.
Cash-Pay
No reimbursement cycles and no payer margin erosion on the core service lines.
Required
An independent, state-licensed Medical Director directs all clinical care. You own and operate the business.
Launched
By our team, with 30+ years of combined experience. We help founders open in all 50 states.
Launch Window
From keys received, market and regulatory conditions permitting.
This category has a regulatory history many operators have never read. Straight answers below, including the uncomfortable ones; anything else, ask on the strategy call.
View All FAQs
Half the market, a fraction of the competition. Talk with Grayson Miller about local demand, the device and claims picture, and what opening takes. No pitch. No obligation.
ACG is a consulting and advisory firm, not a medical practice; an independent, state-licensed Medical Director directs all clinical care. Results are not guarantees of income. Individual outcomes vary. The 60-day target begins from clinic keys received, market and regulatory conditions permitting.
Knowing the rules is the foundation of every clinic we help launch.
You own and run the business. An independent, state-licensed Medical Director makes every clinical, prescribing and treatment decision, structured for your state's Corporate Practice of Medicine laws. We connect you to a vetted network; you retain your own provider.
PRP, peptides, GLP-1 medications and cellular products each carry federal and state rules, and not every product or use is FDA-approved. Exosomes for therapeutic use are not FDA-approved at all, and we steer you away from them. Your menu and marketing are built to hold up to FDA, FTC and state medical board scrutiny.
We show real ranges and never promise an income or a clinical outcome. What you earn depends on your market, your capital and your execution.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe or sell any drug, biologic, device or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the compliance of every product, therapy and claim. See the full regulatory notice below.